Dakota Wealth Management Has $647,000 Stock Holdings in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Dakota Wealth Management cut its position in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 11.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,270 shares of the company’s stock after selling 1,200 shares during the period. Dakota Wealth Management owned 0.23% of Invesco Biotechnology & Genome ETF worth $647,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of PBE. Carnegie Investment Counsel acquired a new position in Invesco Biotechnology & Genome ETF in the 3rd quarter valued at about $204,000. Cetera Investment Advisers grew its stake in Invesco Biotechnology & Genome ETF by 2.1% in the 2nd quarter. Cetera Investment Advisers now owns 27,893 shares of the company’s stock valued at $1,808,000 after buying an additional 561 shares during the last quarter. One Capital Management LLC grew its stake in Invesco Biotechnology & Genome ETF by 31.9% in the 2nd quarter. One Capital Management LLC now owns 25,402 shares of the company’s stock valued at $1,646,000 after buying an additional 6,137 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in Invesco Biotechnology & Genome ETF in the 2nd quarter valued at about $26,000. Finally, Massachusetts Wealth Management grew its stake in Invesco Biotechnology & Genome ETF by 15.3% in the 2nd quarter. Massachusetts Wealth Management now owns 16,944 shares of the company’s stock valued at $1,098,000 after buying an additional 2,245 shares during the last quarter.

Invesco Biotechnology & Genome ETF Stock Performance

Shares of PBE opened at $67.11 on Monday. Invesco Biotechnology & Genome ETF has a 52 week low of $52.47 and a 52 week high of $72.72. The firm has a market cap of $271.12 million, a P/E ratio of 17.12 and a beta of 0.88. The firm’s 50-day simple moving average is $69.88 and its 200 day simple moving average is $66.77.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.